{
    "id": 24891,
    "fullName": "TFG - ROS1",
    "impact": "fusion",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "TFG-ROS1 results from the fusion of TFG and ROS1 (PMID: 24875859). TFG-ROS1 has been identified in inflammatory myofibroblastic tumors (PMID: 24875859), atypical meningioma (PMID: 28449809), and non-small cell lung carcinoma (Journal of Thoracic Oncology, Vol. 13, Issue 9, 1373-1382), but has not been biochemically characterized and therefore, the effect on protein function is unknown (PubMed, Nov 2019).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 14831,
                    "pubMedId": 28449809,
                    "title": "Genomic diagnostics leading to the identification of a TFG-ROS1 fusion in a child with possible atypical meningioma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28449809"
                },
                {
                    "id": 14832,
                    "pubMedId": null,
                    "title": "Characteristics and Outcome of ROS1-Positive Non\u2013Small Cell Lung Cancer Patients in Routine Clinical Practice",
                    "url": "https://www.jto.org/article/S1556-0864(18)30673-7/pdf"
                },
                {
                    "id": 6382,
                    "pubMedId": 24875859,
                    "title": "Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24875859"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 10342,
        "geneSymbol": "TFG",
        "terms": [
            "TFG",
            "HMSNP",
            "SPG57",
            "TF6",
            "TRKT3"
        ]
    },
    "variant": "TFG - ROS1",
    "createDate": "07/28/2016",
    "updateDate": "11/05/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 6098,
                "geneSymbol": "ROS1",
                "terms": [
                    "ROS1",
                    "c-ros-1",
                    "MCF3",
                    "ROS"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 14204,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Rozlytrek (entrectinib) treatment resulted in an objective response in a pediatric patient with inflammatory myofibroblastic tumor harboring TFG-ROS1 fusion (J Clin Oncol 36, 2018 (suppl; abstr 10536); NCT02650401).",
            "molecularProfile": {
                "id": 25651,
                "profileName": "TFG - ROS1"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 50905,
                "name": "inflammatory myofibroblastic tumor",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11509,
                    "pubMedId": null,
                    "title": "Phase 1 study of entrectinib (RXDX-101), a TRK, ROS1, and ALK inhibitor, in children, adolescents, and young adults with recurrent or refractory solid tumors.",
                    "url": "https://meetinglibrary.asco.org/record/162773/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7509,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Xalkori (crizotinib) treatment resulted in sustained tumor regression (more than 4 months) in a pediatric patient with an inflammatory myofibroblastic tumor harboring a TFG-ROS1 fusion (PMID: 24875859).",
            "molecularProfile": {
                "id": 25651,
                "profileName": "TFG - ROS1"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 50905,
                "name": "inflammatory myofibroblastic tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6382,
                    "pubMedId": 24875859,
                    "title": "Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24875859"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 25651,
            "profileName": "TFG - ROS1",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}